NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will participate in an upcoming virtual investor conference:
To learn more or to schedule a one-on-one meeting with management, please contact your conference representative or james@haydenir.com.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).
In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James Carbonara
(646)-755-7412
james@haydenir.com
Reduces Waystar's cost of capital and enhances its ability to allocate free cash flow towards…
HOUSTON, June 27, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:…
License provides exclusive access to innovative epigenetic editors and expands the reach of Chroma's platform…
Nationwide Walk Series Kicks Off July 20 in Pittsburgh CHICAGO, June 27, 2024 /PRNewswire/ --…
This unique, proprietary service is exclusively available to Magnolia Medical customers as part of its…
The Venture Capital Firm Set to Expand Investments in Innovative Healthcare Companies NEW YORK, June…